What Weight Do You Have to Be for Ozempic?

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Many people wonder whether they must reach a certain weight before becoming eligible for Ozempic or semaglutide therapy. The truth is more nuanced: prescription criteria depend on BMI category, comorbidities, and metabolic risk factors—not an absolute weight cutoff. Understanding these clinical guidelines helps you determine whether GLP-1 receptor agonist treatment aligns with your health goals.

FDA Eligibility Criteria for Semaglutide Weight Loss

The FDA approved semaglutide (Ozempic, Wegovy) for chronic weight management in patients with a BMI of 30 kg/m² or higher, or those with a BMI of 27 kg/m² or greater who also have at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. This framework means two people of different weights might both qualify, depending on their metabolic health profile. Your actual body weight matters less than your BMI category and overall health status.

PlexusDx evaluates your eligibility through a comprehensive health intake that captures your BMI, medical history, and current medications. Licensed clinicians then determine whether semaglutide aligns with your specific situation, ensuring treatment is both safe and effective. This personalized approach differs from simply checking a weight threshold.

BMI vs. Body Weight: What Actually Matters

Body Mass Index (BMI) is calculated by dividing your weight in kilograms by your height in meters squared. A BMI of 30 or above is classified as obese, while 25–29.9 is classified as overweight. However, BMI is one tool among many—muscle mass, bone density, age, and ethnicity can all affect how BMI relates to actual health risk. Two people weighing the same may have different BMIs based on height, and two people with identical BMIs may have vastly different health profiles.

When considering semaglutide therapy, clinicians look beyond the BMI number to assess insulin resistance, blood sugar control, cardiovascular risk, and inflammatory markers. This holistic view helps identify whether GLP-1 treatment will address your underlying metabolic dysfunction, not just reduce your scale reading.

Medical Conditions That Lower the BMI Threshold

If you have type 2 diabetes, prediabetes, hypertension, obstructive sleep apnea, or established cardiovascular disease, you may qualify for semaglutide at a BMI as low as 27 kg/m². This lower threshold reflects FDA recognition that these conditions amplify weight-related health risks. Many patients with BMI 27–29 who carry significant metabolic burden benefit substantially from GLP-1 therapy before reaching a BMI of 30.

Metabolic syndrome—a cluster of high blood sugar, high blood pressure, high triglycerides, and abdominal fat distribution—is another key factor. Even if your BMI sits just above 25, evidence of metabolic dysfunction can warrant semaglutide consideration. PlexusDx clinicians assess these interconnected markers during intake to match you with the right treatment approach.

How PlexusDx Determines Your Semaglutide Candidacy

PlexusDx starts with a detailed health questionnaire, vital measurements, and a review of your recent labs if available. This information feeds into a clinical decision framework that considers your BMI, comorbidities, medication interactions, kidney and liver function, and personal weight-loss history. Rather than applying a one-size-fits-all weight threshold, PlexusDx tailors eligibility assessment to your unique physiology and goals.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do I need to weigh a specific amount to get prescribed semaglutide?

No. Semaglutide eligibility is determined by BMI category (30+, or 27+ with weight-related conditions), not an absolute weight number. Two people of different body weights might both qualify if their BMI and health profile support it. PlexusDx clinicians assess your entire metabolic picture during intake.

What if my BMI is 28 and I have prediabetes—am I eligible?

Yes. Prediabetes is a weight-related condition that qualifies you for semaglutide at a BMI as low as 27. PlexusDx evaluates your fasting glucose, HbA1c, and insulin resistance markers to confirm candidacy and determine whether GLP-1 therapy can help reverse metabolic dysfunction before progression to type 2 diabetes.

How much does semaglutide cost at PlexusDx, and does price change with dose?

Compounded semaglutide injection at PlexusDx is $189/mo month-to-month (or $149/mo on the 6-month plan) on a flat-rate basis—your price remains the same whether your dose increases over time. PlexusDx also accepts HSA and FSA funds, making treatment more accessible without insurance requirements.

Is weight loss guaranteed once I meet the BMI threshold for semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What is the Precision Peptide Genetic Test, and does it affect my eligibility?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Losing Weight
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.